Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
SNSS [NASD]
Sunesis Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.73 Insider Own0.30% Shs Outstand60.42M Perf Week27.83%
Market Cap88.82M Forward P/E- EPS next Y-0.49 Insider Trans-98.20% Shs Float59.92M Perf Month-79.41%
Income-41.10M PEG- EPS next Q-0.17 Inst Own73.80% Short Float18.07% Perf Quarter-76.25%
Sales8.00M P/S11.10 EPS this Y27.50% Inst Trans15.06% Short Ratio5.26 Perf Half Y-72.21%
Book/sh0.26 P/B5.65 EPS next Y33.80% ROA-75.40% Target Price1.96 Perf Year-68.72%
Cash/sh0.97 P/C1.52 EPS next 5Y- ROE-556.80% 52W Range1.00 - 8.46 Perf YTD-68.99%
Dividend- P/FCF- EPS past 5Y36.70% ROI-268.60% 52W High-82.62% Beta2.92
Dividend %- Quick Ratio1.50 Sales past 5Y8.20% Gross Margin- 52W Low47.00% ATR0.42
Employees32 Current Ratio1.50 Sales Q/Q0.00% Oper. Margin- RSI (14)21.51 Volatility10.10% 12.97%
OptionableYes Debt/Eq0.87 EPS Q/Q-25.00% Profit Margin- Rel Volume1.32 Prev Close1.50
ShortableYes LT Debt/Eq0.27 EarningsAug 05 BMO Payout- Avg Volume2.06M Price1.47
Recom3.00 SMA20-62.49% SMA50-75.26% SMA200-74.48% Volume2,724,344 Change-2.00%
07-Oct-14Downgrade ROTH Capital Buy → Neutral $15 → $1.30
07-Oct-14Downgrade RBC Capital Mkts Outperform → Sector Perform $9 → $3
12-Jun-14Initiated UBS Buy $14
11-Sep-12Reiterated Cantor Fitzgerald Buy $6 → $8
29-May-12Upgrade RBC Capital Mkts Sector Perform → Outperform $3 → $5
13-Apr-12Initiated Cantor Fitzgerald Buy $6
06-Mar-12Initiated Canaccord Genuity Buy $4
11-Oct-11Downgrade RBC Capital Mkts Outperform → Sector Perform $4 → $3
29-Sep-11Initiated MLV Capital Buy $3.50
15-Oct-14 08:29AM  Sunesis Pharmaceuticals (SNSS) Jumps: Stock Gains 8.5% Zacks +7.83%
09-Oct-14 08:31AM  The Zacks Analyst Blog Highlights: Sunesis Pharmaceuticals, Chimerix, Regeneron and Incyte Zacks -13.29%
08-Oct-14 07:14AM  Biotech Stock Roundup: Sunesis Tanks on Study Results, Chimerix Up on Ebola Update Zacks +5.93%
07-Oct-14 04:19PM  Sunesis Pharmaceuticals, Inc.'s Flop: More Drugs Out There, Says Roth Benzinga -7.53%
03:40PM  Sunesis Pharmaceuticals Down on Failure of Trial on Qinprezo Zacks
11:39AM  It's True, Small-Cap Biotech Stocks Are Acting Badly These Days at TheStreet
08:29AM  Mondays Notable Options Activity: WhatsApp with Facebook? Yahoo Finance Blogs
05:57AM  Sunesis Pharma downgraded by ROTH Capital and RBC Capital Mkts Briefing.com
06-Oct-14 02:00PM  U.S. Stocks Turn Red; CareFusion Shares Surge On Announcement Of Acquisition By Becton, Dickinson Benzinga -78.01%
12:46PM  Midday movers: Chimerix, H&R Block, McDonald's & More at CNBC
11:54AM  [video] Stocks Push Back After Opening Higher, Nasdaq Erases Gains at TheStreet
11:31AM  Why Sunesis Pharmaceuticals (SNSS) Stock Hit a One-Year Low Today at TheStreet
10:58AM  Markets Open Higher; Hewlett-Packard Plans To Split Into Two Companies Benzinga
08:46AM  US STOCKS-Small biotech stocks plummet in premarket Reuters
08:41AM  A one-day fling for stocks, and fret more over gold than over the dollar at MarketWatch
08:28AM  Ahead of the Bell: Sunesis Pharma shares sink AP
07:41AM  Sunesis Pharma shares crater after failed cancer drug trial at MarketWatch
07:00AM  Sunesis Drug for Elderly Blood Cancer Patients Fails Phase III Study at TheStreet
06:37AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
06:30AM  Sunesis Announces Results From Pivotal Phase 3 VALOR Trial of Vosaroxin and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia GlobeNewswire
04-Sep-14 07:00AM  Sunesis to Present at the 2014 Morgan Stanley Global Healthcare Conference GlobeNewswire
02-Sep-14 10:29AM  Sunesis Takes a Run Through the Feuerstein-Ratain Rule at TheStreet
28-Aug-14 06:43AM  Sunesis Pharmaceuticals (SNSS) in Focus: Stock Rises 9.9% Zacks -5.47%
27-Aug-14 04:05PM  UBS Says Sunesis Leukemia Pivotal Trial Success 'Likely' Benzinga +9.88%
26-Aug-14 10:02AM  Weak On High Volume: Sunesis Pharmaceuticals (SNSS) at TheStreet
09:50AM  Your September Biotech Back-to-School Calendar at TheStreet
15-Aug-14 01:04PM  SUNESIS PHARMACEUTICALS INC Financials EDGAR Online Financials
06-Aug-14 08:19AM  Sunesis Pharmaceuticals, Inc. (SNSS) Jumps: Stock Rises 9% Zacks
07:00AM  Sunesis to Present at the 2014 Wedbush Life Sciences Management Access Conference GlobeNewswire
05-Aug-14 11:00AM  Sunesis Pharmaceuticals Inc Earnings Call scheduled for 11:00 am ET today CCBN +9.02%
08:02AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
07:07AM  Q2 2014 Sunesis Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
07:00AM  Sunesis Pharmaceuticals Reports Second Quarter 2014 Financial Results and Recent Highlights GlobeNewswire
29-Jul-14 07:00AM  Sunesis to Host Conference Call on August 5th to Discuss Second Quarter 2014 Financial Results and Recent Highlights GlobeNewswire
14-Jul-14 05:45PM  Sunesis' Pediatric Plan Accepted in the EU Zacks
09-Jul-14 08:42AM  Better Buy: Clovis Oncology vs. Sunesis Pharmaceuticals at Motley Fool
07:04AM  Sunesis Pharmaceuticals Announces European Medicines Agency Acceptance of Pediatric Investigation Plan for Qinprezo For AML Benzinga
07:00AM  Sunesis Pharmaceuticals Announces European Medicines Agency Acceptance of Pediatric Investigation Plan for Qinprezo(TM) (Vosaroxin) for AML GlobeNewswire
13-Jun-14 07:11AM  Sunesis Pharmaceuticals (SNSS) Soars: Stock Adds 8% in Session Zacks
12-Jun-14 09:13AM  On The Fly: Pre-market Movers at theflyonthewall.com +7.96%
11-Jun-14 07:00AM  Sunesis to Present at the 2014 Wells Fargo Healthcare Conference GlobeNewswire
09-Jun-14 04:24PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
02-Jun-14 07:16AM  Sunesis says encouraged by trial of Qinprezo at theflyonthewall.com
07:00AM  Sunesis Announces Presentation of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS at ASCO 2014 Annual Meeting GlobeNewswire
14-May-14 07:00AM  Sunesis to Present at Upcoming Investor Conferences GlobeNewswire
09-May-14 11:14AM  Sunesis Pharmaceuticals Inc Stock Downgraded (SNSS) at TheStreet +5.25%
08-May-14 06:52AM  Is Sunesis Pharmaceuticals Poised for a Breakout? at Motley Fool
07-May-14 02:00PM  Sunesis Pharmaceuticals' (SNSS) CEO Daniel Swisher on Q1 2014 Results - Earnings Call Transcript at Seeking Alpha
11:00AM  Sunesis Pharmaceuticals, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
08:03AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
07:07AM  Q1 2014 Sunesis Pharmaceuticals, Inc. Earnings Release - Before Market Open CCBN
07:00AM  Sunesis Pharmaceuticals Reports First Quarter 2014 Financial Results and Recent Highlights GlobeNewswire
30-Apr-14 07:00AM  Sunesis to Host Conference Call on May 7th to Discuss First Quarter 2014 Financial Results and Recent Highlights GlobeNewswire
29-Apr-14 06:31PM  3 Ways Ariad Pharmaceuticals Could Mount a Comeback at Motley Fool
22-Apr-14 07:00AM  Sunesis Announces MD Anderson Sponsored Study of Vosaroxin in AML and High-Risk MDS Poster to be Presented at ASCO 2014 GlobeNewswire +8.16%
10-Apr-14 06:31PM  2 Biotech Stocks to Watch: Merrimack Pharmaceuticals and Sunesis Pharmaceuticals at Motley Fool -8.75%
08-Apr-14 01:30PM  Sunesis vosaroxin shown to be effective, says Wedbush at theflyonthewall.com
11:00AM  Sunesis Pharmaceuticals Update Call to Discuss Poster Presented at the AACR Annual Meeting scheduled for 11:00 am ET today CCBN
08:00AM  Sunesis Announces Presentation of Positive Results From Ongoing MD Anderson-Sponsored Trial of Vosaroxin in AML and High-Risk MDS GlobeNewswire
07-Apr-14 11:17AM  Is Now the Time to Invest in Agios Pharmaceuticals, Inc? at Motley Fool
02-Apr-14 07:00AM  Sunesis Announces MD Anderson Sponsored Trial of Vosaroxin in AML and High-Risk MDS Poster to be Presented at AACR 2014 GlobeNewswire +5.02%
31-Mar-14 07:04PM  Nasdaq stocks posting largest percentage decreases AP +5.93%
24-Mar-14 04:03PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E EDGAR Online
06-Mar-14 02:40PM  Sunesis Pharmaceuticals Management Discusses Q4 2013 Results - Earnings Call Transcript at Seeking Alpha
11:00AM  Sunesis Pharmaceuticals, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
08:03AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a EDGAR Online
07:07AM  Q4 2013 Sunesis Pharmaceuticals, Inc. Earnings Release - Time Not Supplied CCBN
07:00AM  Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights GlobeNewswire
05-Mar-14 07:46AM  Sunesis (SNSS) Jumps: Stock Moves 6.8% Higher Zacks
28-Feb-14 04:52PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers EDGAR Online
08:18AM  Sunesis to Present at Upcoming Investor Conferences GlobeNewswire
08:17AM  Sunesis to Host Conference Call on March 6th to Discuss Fourth Quarter and Full-Year 2013 Financial Results and Recent Highlights GlobeNewswire
27-Feb-14 06:42PM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and EDGAR Online
08:44AM  Sunesis raises $43M in common stock and warrants offering theflyonthewall.com
08:30AM  Sunesis Announces Pricing of a $43.0 Million Public Offering of Common Stock and Warrants GlobeNewswire
26-Feb-14 04:13PM  Sunesis Announces Proposed Public Offering of Common Stock and Warrants GlobeNewswire +5.33%
01:51PM  Nasdaq stocks posting largest percentage increases AP
25-Feb-14 07:49AM  Sunesis risk/reward attractive at current levels, says Leerink theflyonthewall.com +17.46%
19-Feb-14 04:01AM  3 Small Cap Biotechs Developing Novel Cancer Treatments at Motley Fool
11-Feb-14 07:33AM  Sunesis Pharmaceuticals (SNSS) Falls: Stock Goes Down 5.4% Zacks
10-Feb-14 08:01AM  SUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online -5.42%
07:26AM  Sunesis announces vosaroxin Phase 3 VALOR trial unblinding expected in Q3 theflyonthewall.com
07:15AM  Sunesis (SNSS) Catches Eye: Stock Soars 18.3% Zacks
07:00AM  Sunesis Appoints Joseph I. DePinto as Chief Commercial Officer, Updates VALOR Timeline to Unblinding of Data GlobeNewswire
06-Feb-14 07:24AM  Sunesis Pharmaceuticals (SNSS) Sees Hammer Chart Pattern: Time to Buy? Zacks
07:05AM  Sunesis to Present at Upcoming Investor Conferences GlobeNewswire
17-Jan-14 03:52PM  Five Worst, Pandering Drug Stocks of J.P. Morgan Healthcare Confab Week at TheStreet
09-Jan-14 11:00AM  Sunesis Pharmaceuticals Expands Hematology Franchise Call scheduled for 11:00 am ET today CCBN
07:00AM  Sunesis Pharmaceuticals Expands Hematology Franchise With Global Licenses to Two Kinase Inhibitor Programs GlobeNewswire
26-Dec-13 01:47AM  Idenix Pharmaceuticals (IDIX) Soars: Stock Adds 18.2% in Session Zacks
17-Dec-13 07:33AM  Sunesis Pharmaceuticals, Inc. is now in Oversold Territory Zacks
Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. The company's lead product candidate is vosaroxin, an anti-cancer quinolone derivative for the treatment of acute myeloid leukemia or AML. It has completed a Phase III, randomized, double-blind, placebo-controlled, and pivotal clinical trial of vosaroxin in combination with cytarabine in patients with relapsed or refractory AMl. The company also completed a Phase II single-agent trial of vosaroxin in platinum-resistant ovarian cancer. In addition, it is involved in the initiation of an investigator-sponsored trial of vosaroxin in combination with decitabine in older patients with untreated AML and high-risk myelodysplastic syndrome. Sunesis Pharmaceuticals, Inc. has a collaboration agreement with Biogen Idec to discover, develop, and commercialize small molecule inhibitors of the human protein Raf kinase; and licensing agreements with Millennium to provide worldwide license to develop and commercialize preclinical inhibitors of PDK1. The company was founded in 1998 and is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Growth Equity Opportunities Fu10% OwnerAug 29Sale7.5111,60087,0704,659,333Aug 29 05:37 PM
DRANT RYAN D10% OwnerAug 29Sale7.5111,60087,0704,659,333Aug 29 05:40 PM
BARRIS PETER J10% OwnerAug 29Sale7.5111,60087,0704,659,333Aug 29 05:39 PM
BASKETT FOREST10% OwnerAug 29Sale7.5111,60087,0704,659,333Aug 29 05:39 PM
BARRETT M JAMES10% OwnerAug 29Sale7.5111,60087,0704,659,333Aug 29 05:38 PM
KERINS PATRICK J10% OwnerAug 29Sale7.5111,60087,0704,659,333Aug 29 05:41 PM
KOLLURI KRISHNA KITTU10% OwnerAug 29Sale7.5111,60087,0704,659,333Aug 29 05:41 PM
KOLLURI KRISHNA KITTU10% OwnerAug 28Sale7.87146,8001,154,8464,670,933Aug 29 05:41 PM
KERINS PATRICK J10% OwnerAug 28Sale7.87146,8001,154,8464,670,933Aug 29 05:41 PM
BARRETT M JAMES10% OwnerAug 28Sale7.87146,8001,154,8464,670,933Aug 29 05:38 PM
BASKETT FOREST10% OwnerAug 28Sale7.87146,8001,154,8464,670,933Aug 29 05:39 PM
BARRIS PETER J10% OwnerAug 28Sale7.87146,8001,154,8464,670,933Aug 29 05:39 PM
DRANT RYAN D10% OwnerAug 28Sale7.87146,8001,154,8464,670,933Aug 29 05:40 PM
Misfeldt DaytonDirectorAug 28Sale7.89200,0001,577,02085,872Aug 29 06:31 PM
BAY CITY CAPITAL LLC10% OwnerAug 28Sale7.89200,0001,577,0204,593,687Aug 29 04:05 PM
Growth Equity Opportunities Fu10% OwnerAug 28Sale7.87146,8001,154,8464,670,933Aug 29 05:37 PM
Swisher Daniel N JRPresident and CEOAug 27Option Exercise2.095,00010,450159,073Aug 29 06:02 PM
BJERKHOLT ERICEVP, CFO & Corp. SecretaryAug 27Option Exercise1.7410,00017,40049,994Aug 29 06:04 PM
Misfeldt DaytonDirectorAug 27Sale8.16100,700822,01489,612Aug 29 06:31 PM
Craig Adam REVP, Development & CMOAug 27Sale8.002,55420,43212,723Aug 29 06:05 PM
BJERKHOLT ERICEVP, CFO & Corp. SecretaryAug 27Sale8.0010,00080,00039,994Aug 29 06:04 PM
Swisher Daniel N JRPresident and CEOAug 27Sale8.005,00040,000154,073Aug 29 06:02 PM
BAY CITY CAPITAL LLC10% OwnerAug 27Sale8.16100,700822,0144,793,687Aug 29 04:05 PM
Growth Equity Opportunities Fu10% OwnerAug 27Sale8.17108,300884,8114,817,733Aug 29 05:37 PM
DRANT RYAN D10% OwnerAug 27Sale8.17108,300884,8114,817,733Aug 29 05:40 PM
BARRIS PETER J10% OwnerAug 27Sale8.17108,300884,8114,817,733Aug 29 05:39 PM
BASKETT FOREST10% OwnerAug 27Sale8.17108,300884,8114,817,733Aug 29 05:39 PM
BARRETT M JAMES10% OwnerAug 27Sale8.17108,300884,8114,817,733Aug 29 05:38 PM
KERINS PATRICK J10% OwnerAug 27Sale8.17108,300884,8114,817,733Aug 29 05:41 PM
KOLLURI KRISHNA KITTU10% OwnerAug 27Sale8.17108,300884,8114,817,733Aug 29 05:41 PM
Growth Equity Opportunities Fu10% OwnerAug 12Sale6.7635,540240,1904,926,033Aug 12 05:39 PM
BARRETT M JAMES10% OwnerAug 12Sale6.7635,540240,1904,926,033Aug 12 05:41 PM
DRANT RYAN D10% OwnerAug 12Sale6.7635,540240,1904,926,033Aug 12 05:44 PM
BASKETT FOREST10% OwnerAug 12Sale6.7635,540240,1904,926,033Aug 12 05:44 PM
BARRIS PETER J10% OwnerAug 12Sale6.7635,540240,1904,926,033Aug 12 05:44 PM
KOLLURI KRISHNA KITTU10% OwnerAug 12Sale6.7635,540240,1904,926,033Aug 12 05:45 PM
Misfeldt DaytonDirectorAug 12Sale6.7737,100251,23091,495Aug 12 08:49 PM
KERINS PATRICK J10% OwnerAug 12Sale6.7635,540240,1904,926,033Aug 12 05:44 PM
BAY CITY CAPITAL LLC10% OwnerAug 12Sale6.7737,100251,2304,894,387Aug 12 05:54 PM
BAY CITY CAPITAL LLC10% OwnerAug 11Sale6.9031,600218,1034,931,487Aug 12 05:54 PM
Misfeldt DaytonDirectorAug 11Sale6.9031,600218,10392,189Aug 12 08:49 PM
Misfeldt DaytonDirectorAug 08Sale6.62675,0004,468,56892,780Aug 12 08:49 PM
BAY CITY CAPITAL LLC10% OwnerAug 08Sale6.62675,0004,468,5684,963,087Aug 12 05:54 PM
KERINS PATRICK J10% OwnerAug 08Sale6.62675,0004,468,5684,961,573Aug 12 05:44 PM
KOLLURI KRISHNA KITTU10% OwnerAug 08Sale6.62675,0004,468,5684,961,573Aug 12 05:45 PM
BARRIS PETER J10% OwnerAug 08Sale6.62675,0004,468,5684,961,573Aug 12 05:44 PM
BASKETT FOREST10% OwnerAug 08Sale6.62675,0004,468,5684,961,573Aug 12 05:44 PM
DRANT RYAN D10% OwnerAug 08Sale6.62675,0004,468,5684,961,573Aug 12 05:44 PM
BARRETT M JAMES10% OwnerAug 08Sale6.62675,0004,468,5684,961,573Aug 12 05:41 PM
Growth Equity Opportunities Fu10% OwnerAug 08Sale6.62675,0004,468,5684,961,573Aug 12 05:39 PM
Swisher Daniel N JRPresident and CEOMay 16Option Exercise2.0924,38950,973152,406May 19 05:11 PM
Ketchum Steven BDirectorNov 08Option Exercise2.0910,50321,95184,464Apr 02 07:29 PM
Ketchum Steven BDirectorNov 08Sale5.0810,50353,36473,961Apr 02 07:29 PM
Ketchum Steven BDirectorNov 07Option Exercise2.0919,55140,86293,512Apr 02 07:29 PM
Ketchum Steven BDirectorNov 07Sale5.0319,55198,29573,961Apr 02 07:29 PM